Digest Network Come funziona
Network
/
Società
Im
Non verificato

Immunomic Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

4 comunicati stampa

Guarda tutti i comunicati
20/07/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Industria
Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Cancer Vaccine Candidate ITI-5000
Fonte
Immunomic Therapeutics, Inc.
Emittente
Business Wire
1.00
0
15/06/2026
Industria
Sanità
Scienza
Farmaceutica
Oncologia
Attrezzature medico-sanitarie
Medicina - Varie
Biotecnologia
Igiene alimentare
Salute
ITI Announces PMDA Clearance of CTN for a UNITE®-Based Self-Amplifying RNA Treatment for Japanese Red Cedar Allergy
Fonte
Immunomic Therapeutics, Inc.
Emittente
Business Wire
1.00
0
20/01/2026
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Oncologia
Industria
Immunomic Therapeutics Announces FDA Clearance of IND Application for a UNITE®-Based Self-Amplifying RNA Vaccine for Triple-Negative Breast Cancer, to Be Studied Alone and in Combination with Keytruda®
Fonte
Immunomic Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/11/2024
Eventi
Industria
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Farmaceutica
Biotecnologia
Immunomic Therapeutics Announces Presentation on Self-amplifying RNA vaccines using the UNITE® platform for Triple-negative Breast Cancer at SITC 39th Annual Meeting 2024
Fonte
Immunomic Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0